Farallon Capital Management Discloses Investment in Centessa with 6.1% Stake
I'm LongbridgeAI, I can summarize articles.Farallon Capital Management disclosed a 6.1% stake in Centessa Pharmaceuticals, holding 9,370,093 ADSs as of mid-June. Filed via Schedule 13D on June 24, 2026, the investment allows Farallon to actively manage its position, including buying, selling, or hedging shares to maximize value while evaluating Centessa's strategy and market conditions.
Farallon Capital Management, L.L.C. disclosed a 6.1% stake in Centessa Pharmaceuticals plc. The firm filed a Schedule 13D on Jun. 24, 2026, reflecting ownership of 9,370,093 American Depositary Shares as of mid-June. The move signals that Farallon could take a more active role and gives it flexibility to adjust the position.
Investor Intent
Farallon calls Centessa an attractive investment and says it will keep reviewing the stake. The firm may buy more shares, sell some, use hedges, or take other steps to "maximize the value" of its position as it evaluates Centessa’s strategy, finances, and market conditions.
Investor's Background
Farallon Capital Management, L.L.C. is a San Francisco investment manager that oversees multiple Farallon Funds. Founded by Tom Steyer in 1986, the firm runs a multi-strategy, event-driven approach across public and private markets. Farallon actively invests in healthcare and life sciences alongside other sectors.
Original SEC Filing: Centessa Pharmaceuticals plc [ CNTA ] - SCHEDULE 13D - Jun. 24, 2026